SCHEMBL31577219

SCHEMBL31577219

CNc1nc(Nc2ccc(N3CC(N(C)C)C3)cc2)cnc1-c1cncc2c1ncn2C

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ HTR3A P46098 1/20 0.30
▸ WEE1 P30291 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173404 0.85 MAPK10 (0.40) —
SCHEMBL29173301 0.83 BTK (0.39) —
SCHEMBL31577249 0.83 WEE1 (0.31) WEE1
SCHEMBL30206216 0.82 EGFR (0.33) —
SCHEMBL29173389 0.82 EGFR (0.33) —
SCHEMBL31577230 0.81 FGFR4 (0.36) WEE1
Formic Acid SCHEMBL30205747 0.81 BTK (0.37) —
SCHEMBL31577209 0.79 WEE1 (0.35) WEE1
SCHEMBL29173642 0.78 SYK (0.38) —
SCHEMBL31577202 0.77 CDK1 (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
Send feedback